cyteir

About cyteir

This author has not yet filled in any details.
So far cyteir has created 5 blog entries.

Cyteir Therapeutics Presents Preclinical Data Validating RAD51-AID as a Novel Target for Cancer Treatment at American Association of Cancer Research Annual Meeting

2018-02-11T00:24:20+00:00

Cyteir Therapeutics Presents Preclinical Data Validating RAD51-AID as a Novel Target for Cancer Treatment at American Association of Cancer Research Annual Meeting    -- Preclinical data elucidates mechanism and demonstrates successful intervention with small molecules in leukemia and lymphoid cancer models --   -- Clinical candidate expected to be identified in 2017 --  CAMBRIDGE, Mass. – March 28, [...]

Cyteir Therapeutics Presents Preclinical Data Validating RAD51-AID as a Novel Target for Cancer Treatment at American Association of Cancer Research Annual Meeting 2018-02-11T00:24:20+00:00

Cyteir Therapeutics Presents Preclinical Data on Use of DNA Repair Modulators for Lymphoid Malignancies at American Society of Hematology Annual Meeting

2018-02-09T23:38:24+00:00

Cyteir Therapeutics Presents Preclinical Data on Use of DNA Repair Modulators for Lymphoid Malignancies at American Society of Hematology Annual Meeting    -- Preclinical data elucidates mechanism of cell death response to selectively target lymphoid cancers --  CAMBRIDGE, Mass. – November 29, 2016 – Cyteir Therapeutics, Inc., a leader in the development of novel therapeutics based on [...]

Cyteir Therapeutics Presents Preclinical Data on Use of DNA Repair Modulators for Lymphoid Malignancies at American Society of Hematology Annual Meeting 2018-02-09T23:38:24+00:00

Cyteir Therapeutics Receives $2M Grant from National Cancer Institute 

2018-02-09T23:40:03+00:00

Cyteir Therapeutics Receives $2M Grant from National Cancer Institute  CAMBRIDGE, Mass. – June 29, 2016 – Cyteir Therapeutics, Inc., a leader in the development of novel therapeutics based on the biology of DNA repair, today announced that it has received a $2 million, two-year grant from the National Cancer Institute (NCI), part of the National Institutes of [...]

Cyteir Therapeutics Receives $2M Grant from National Cancer Institute  2018-02-09T23:40:03+00:00

Cyteir Therapeutics Announces Study Showing RAD51 Modulators Protect Diabetic Mice from Type 1 Diabetes (T1D)

2018-02-11T00:45:58+00:00

Cyteir Therapeutics Announces Study Showing RAD51 Modulators Protect Diabetic Mice from Type 1 Diabetes (T1D)  --Data demonstrates that therapeutic targeting of the AID/RAD51 axis in B cells may block development of T1D by converting B cells to a suppressive population capable of inhibiting disease development --  --First demonstration of synthetic lethal pairs in a [...]

Cyteir Therapeutics Announces Study Showing RAD51 Modulators Protect Diabetic Mice from Type 1 Diabetes (T1D) 2018-02-11T00:45:58+00:00

Jackson Laboratory Spinout Cyteir Therapeutics Inc. Announces $5.5 Million Series A Financing and Appointment of Donald F. Corcoran as President and Chief Executive Officer

2018-02-09T23:41:03+00:00

Jackson Laboratory Spinout Cyteir Therapeutics Inc. Announces $5.5 Million Series A Financing and Appointment of Donald F. Corcoran as President and Chief Executive Officer  Proceeds will provide funding to Cyteir Therapeutics to advance its genomic instability and DNA repair programs  Cambridge, Mass., and Bar Harbor, Maine – November 5, 2015 – Cyteir Therapeutics, a [...]

Jackson Laboratory Spinout Cyteir Therapeutics Inc. Announces $5.5 Million Series A Financing and Appointment of Donald F. Corcoran as President and Chief Executive Officer 2018-02-09T23:41:03+00:00